Literature DB >> 3076609

Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections.

A Romano1, Y Sadan.   

Abstract

This review of ten years of experience presents the results of clinical use of human beta-interferon (Frone) in viral ocular disease. Two forms of human beta-interferon have been used: (a) Frone cream 20,000 IU/g (Inter-Yeda Ltd.) for local treatment and prevention of HSV-1 periocular skin lesions and for Herpes zoster ophthalmicus. (b) Frone eye drops (500,000-1,000,000 U) for prophylaxis and treatment of adenovirus infections and for prevention of recurrent HSV-1 keratitis. Our results show that Frone cream or drops, applied at an early stage, is: (a) Effective in significantly shortening the course of the disease; (b) Has a drying effect on herpetic skin lesions, and tear secretion in adeno viral disease; (c) Reduces the frequency from 1.2 to 0.04 attacks per year for patients with known biological rhythm of the disease; (d) Prevents subepithelial keratitis in 45% of the study population; (e) Prophylactic treatment of interferon in families reduces the incidence of contamination from 65% to 20%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076609

Source DB:  PubMed          Journal:  Metab Pediatr Syst Ophthalmol (1985)        ISSN: 0882-889X


  4 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 2.  Treatment of viral conjunctivitis with antiviral drugs.

Authors:  Chrysanthi L Skevaki; Ioanna E Galani; Michail V Pararas; Konstantina P Giannopoulou; Athanassios Tsakris
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 3.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

Review 4.  Access and barriers to MS care in Latin America.

Authors:  Víctor M Rivera; Miguel Angel Macias
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.